Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients

Autor: Arango, Celso, Giráldez, Miriam, Merchán-Naranjo, Jessica, Baeza, Inmaculada, Castro-Fornieles, Josefina, Alda, Jose-Angel, Martínez-Cantarero, Carmen, Moreno, Carmen, de Andrés, Pilar, Cuerda, Cristina, de la Serna, Elena, Correll, Christoph U., Fraguas, David, Parellada, Mara

Publikováno v: In Journal of the American Academy of Child & Adolescent Psychiatry November 2014 53(11):1179-1190

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All?

Autor: Rodriguez-Otero P; Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Reis J; Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Alfonso-Pierola A; Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Salas-Benito D; Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Giraldez M; Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Azanza JR; Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Ponz-Sarvise M; Paula Rodriguez-Otero, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Joana Reis, Central Unit for Clinical Trials, Clínica Universidad de Navarra, Pamplona, Spain; Ana Alfonso-Pierola, MD, PhD, Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain; Diego Salas-Benito, MD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Miriam Giraldez, PharmD, PhD, Department of Pharmacy, Clínica Universidad de Navarra, Pamplona, Spain; Jose Ramón Azanza, MD, PhD, Department of Clinical Pharmacology, Clínica Universidad de Navarra, Pamplona, Spain; and Mariano Ponz-Sarvise, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.

Publikováno v: JCO global oncology [JCO Glob Oncol] 2020 Jun; Vol. 6, pp. 904-905.